{"filing":{"accession_number":"0001493152-26-025172","cik":"0001412486","ticker":"COCP","company_name":"Cocrystal Pharma, Inc.","form":"8-K","filing_date":"2026-05-26","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315226025172/form8-k.htm"},"events":[{"id":9112,"run_id":7999,"accession_number":"0001493152-26-025172","anchor_item_number":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.55,"summary":"The filing discloses a press release regarding \"novel direct-acting antivirals\" under Item 7.01 (Regulation FD Disclosure). Without access to the actual press release content (Exhibit 99.1), the materiality and specific event type cannot be definitively determined. The disclosure could relate to clinical trial results, product development milestones, or other significant pharmaceutical developments. Given the uncertainty about the substantive content and the lack of a more specific event category that clearly fits, \"other_material\" is the most appropriate classification, with moderate confidence reflecting the information gap.","company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","filing_date":"2026-05-26","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":1615,"accession_number":"0001493152-26-025172","item_number":null,"item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.55,"reasoning":"The filing discloses a press release regarding \"novel direct-acting antivirals\" under Item 7.01 (Regulation FD Disclosure). Without access to the actual press release content (Exhibit 99.1), the materiality and specific event type cannot be definitively determined. The disclosure could relate to clinical trial results, product development milestones, or other significant pharmaceutical developments. Given the uncertainty about the substantive content and the lack of a more specific event category that clearly fits, \"other_material\" is the most appropriate classification, with moderate confidence reflecting the information gap.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:33:28.741160+00:00","company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","filing_date":"2026-05-26"}]}